27th Apr 2021 12:03
SkinBioTherapeutics PLC - Manchester-based life science company focused on the microbiome - Says it has started a research & development programme in oral health with the University of Manchester. Says the 12-month oral health programme will explore the use of different bacteria, including SkinBioTherapeutics' proprietary lysate, SkinBiotix, for oral health and well-being.
"Management believes that focusing on the health of the cells within the oral cavity is a potentially innovative approach to developing a suite of oral healthcare formulations. These formulations could be positioned as standalone products or could work synergistically with traditional oral health and wellbeing products," says SkinBioTherapeutics.
Current stock price: 69.89 pence
Year-to-date change: up over 100% from 23.50 pence at December 31
By Greg Roxburgh; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Skinbiotherap.